Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

Human sera from the United States, Thailand, and sub-Saharan Africa and chimpanzee sera were tested for neutralizing antibodies to 3 chimpanzee adenoviruses. Antibodies were more common in humans residing in sub-Saharan Africa than in humans living in the United States or Thailand. This finding suggests cross-species transmission of chimpanzee adenoviruses.

Neutralizing antibodies to AdHu5 were found in most serum samples from Africa and Thailand. Percentages of antibodies to AdHu5 were higher in serum samples from Africa and Thailand than in serum samples from the United States (Table 1). Titers to AdHu5 were comparable in serum samples from the United States and sub-Saharan Africa but were higher in the control group from Thailand ( Table 2).
Neutralizing antibodies to AdC68, AdC6, and AdC1 were rare in sera from the United States and Thailand, with prevalence rates from 1.5% to 4% (Figure). Most positive samples had titers <80. Of 200 samples from Thailand, only 6 had high titers: 4 to AdC6 and 2 to AdC1. None of the samples from 50 US zoo workers, including those who reported regular contact with primates, had detectable antibodies to chimpanzee adenoviruses.
In contrast, serum samples from sub-Saharan African cohorts had higher prevalences of neutralizing antibodies to chimpanzee adenoviruses (Figure, Table 1). Samples from persons living in Cameroon and Nigeria showed a higher prevalence of neutralizing antibodies to AdC6 and AdC1. Titers of neutralizing antibodies to AdC6 and AdC1 were high, and samples were positive at dilutions >1:80. When compared with sera from Nigeria and Cameroon, sera from Côte d'Ivoire had a different pattern of antibodies reactive to the chimpanzee adenoviruses; prevalence rates were low to AdC1 but higher to AdC68 and AdC6. Although most samples had low to moderate titers, several samples had titers ≥80. No association was found between neutralizing antibodies to AdC68, AdC6, and AdC1 in any of the human samples tested, and only a few human serum samples had neutralizing antibodies to >1 chimpanzee adenovirus (data not shown). One serum sample from Cameroon neutralized all 3 chimpanzee adenoviruses and had titers of 20 to AdC68 and 160 to AdC6 and AdC1.
Circulating neutralizing antibodies to AdHu5 were found in 44% of captive US chimpanzees; titers in chimpanzee samples were comparable to those in human sera, suggesting that AdHu5 can readily cause an infection in captive chimpanzees. The prevalence of antibodies to AdC6 and AdC68 was high and exceeded that of antibodies to AdC1 (Table 1). Titers to AdC68 and AdC6 were higher in chimpanzees than in humans, but titers to AdC1 in both species were similar ( Table 2).

Conclusions
Our data show that as expected, neutralizing antibodies to chimpanzee adenoviruses are rarely found in humans residing in the United States or Thailand. In contrast, their prevalence is higher in human sera from sub-Saharan Africa, where hunting and butchering of nonhuman primates for food are widespread and eating bush meat is com-mon (11). Different prevalence rates of neutralizing antibodies to the 3 chimpanzee adenoviruses in human samples from the 3 African countries tested may reflect different infection rates in chimpanzees residing in these areas.
Cameroon, Gabon, and Republic of Congo are home to most Central African common chimpanzees (Pan troglodytes troglodytes). Most Western common chimpanzees (P. t. verus) inhabit Côte d'Ivoire and Guinea. The rare Nigeria chimpanzee (P. t. vellerosus) is found only in eastern Nigeria and western Cameroon, and Eastern African common chimpanzees (P. t. schweinfurthii) reside in a range from Central African Republic and the Democratic Republic of the Congo through western Uganda and Tanzania. No clear association was found between chimpanzee subspecies and neutralizing antibodies to different chimpanzee adenoviruses. Nevertheless, most samples were from P. t. verus, and only a limited number of samples were from P. t. troglodytes (n = 4) and P. t. schweinfurthii (n = 3). No samples from P. t. vellerosus were tested. In addition, the chimpanzee samples evaluated in the study were from animals kept in captivity and thus may not provide information on distribution of these viruses in free-ranging animals.
Increased prevalence of neutralizing antibodies to chimpanzee adenoviruses in sub-Saharan Africa may reflect cross-species transmission of these viruses from chimpanzees to humans. If transmission occurs, human-tohuman spread of chimpanzee adenoviruses might further contribute to the comparatively high seroprevalence seen in equatorial Africa. Although we have no direct proof for viral cross-species transmission, this process has been previously described for other chimpanzee viruses. For example, the AIDS epidemic is believed to have originated from simian immunodeficiency virus-infected chimpanzees (12). Another chimpanzee retrovirus, simian foamy virus, has been reported to infect persons exposed to primates at zoos and research centers (13) and to infect Bantus in Cameroon (14). Chimpanzee adenoviruses do not appear to spread easily to humans through occupational contact with primates because none of the 23 persons who had routine exposure to primates, including chimpanzees, had serologic evidence of exposure despite the high prevalence of antibodies to chimpanzee adenoviruses in captive US chimpanzees.
Use of chimpanzee adenovirus vectors as vaccines for HIV-1 would require that most persons at high risk for HIV-1 infection lack neutralizing antibodies to these adenoviruses because such antibodies impair induction of transgene product-specific immune responses (4,5). Even in countries where chimpanzees are endemic, neutralizing antibodies to chimpanzee adenoviruses are less common in humans than those directed to AdHu5, which is currently in clinical trials as a vaccine for HIV-1 antigens in a vectored and replication-defective form. An alternative human serotype is AdHu35, which is being developed as a potential vaccine against HIV-1 (15). Prevalence rates to AdHu35 are low in the United States and Europe (<5%); however, rates are markedly higher (<20%) in equatorial Africa (15).
Although neutralizing antibodies to chimpanzee adenoviruses are also relatively more common in human sera from sub-Saharan Africa, they are found less frequently than antibodies to AdHu5 or AdHu35. Nonetheless, increased prevalence of neutralizing antibodies to adenoviruses in countries that are hardest hit by the AIDS pandemic needs to be taken into account in the design of vaccines based on chimpanzee adenovirus vectors. Vectors derived from other species are being developed and may provide additional or alternative vaccine carriers. Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12 ISOPOL represents the premier international meeting on Listeria and listeriosis, and takes place every 3 to 4 years. The 16th international conference in this series will address a wide range of current research and trends related to Listeria, including pathogenesis, genetics and genomics, immunology, epidemiology, risk assessments, clinical aspects, food ecology, evolution, physiology, adaptations, diagnostics and subtyping.
The conference will be of interest to academic researchers; those with clinical, veterinary, public health, and epidemiological interests; regulatory agency representatives; representatives from the food industry; and others with interests in Listeria and listeriosis. The conference will provide abundant opportunities for networking and exchange of information between senior scientists/professionals, students, and young scientists. Plenary sessions and symposia will feature internationally renowned Listeria researchers.

Submit Abstract
To submit an abstract, please visit the conference website at http://www.aphl. org/conferences/ISOPOL.cfm and complete the online submission form. Abstracts must be submitted no later than November 1, 2006.

For More Information
Visit the conference website at http://www.aphl.org/conferences/ ISOPOL.cfm for information on ISOPOL XVI. Questions on registration, logistics, and abstracts should be directed to Terry Reamer at terry.reamer@aphl.org or 240.485.2776. Technical questions should be directed to ISOPOL@cdc.gov.